In the era of opioid crisis, substance use among elderly prostate cancer needs serious consideration. The study objective was to analyze the association between behavioral treatments for substance use and mortality among elderly Medicare patients with advanced stage prostate cancer and substance use disorder (including opioids).
INTRODUCTION AND OBJECTIVES:
In the era of opioid crisis, substance use among elderly prostate cancer needs serious consideration. The study objective was to analyze the association between behavioral treatments for substance use and mortality among elderly Medicare patients with advanced stage prostate cancer and substance use disorder (including opioids).
METHODS: The Surveillance, Epidemiological, and Results (SEER)-Medicare linked databases between 2000 and 2013 were used. From the cohort of men diagnosed with advanced stage prostate cancer between 2001 and 2008, we identified those with a diagnosis of substance use (including opioids). For this cohort of elderly advanced prostate cancer patients who were substance users, we used Medicare claims to determine behavioral treatments for substance use such as psychotherapy (group or individual), drug and alcohol detoxification, case management, and behavioral health counseling (group or individual) . Association between treatment for substance use and five-year mortality was analyzed using Cox regression models.
RESULTS: Of the 3,100 elderly with advanced prostate cancer and substance use disorder, less than 5% had a claim related to behavioral treatment for substance use in the five-year period following their prostate cancer diagnosis. Demographic and clinical attributes were comparable between those receiving behavioral treatment for substance use vs. those not receiving behavioral treatment for substance use. Cox regression results indicated that behavioral treatment for substance use was associated with lower hazard of allcause mortality (HR[0.72, 95% CI[ 0.47, 0.97) , and lower prostate cancer-specific mortality (HR[0.83, 95% CI[ 0.69, 0.94 ), compared to those not receiving behavioral treatment for substance use.
CONCLUSIONS: In elderly advanced stage prostate cancer patients with substance use disorder (including opioids), behavioral treatment for substance use appears to result in survival benefit. Many patients with advanced prostate cancer experience cancer related pain and impaired outcomes. However, the utilization of behavioral treatments for substance use remains low. Along with policies to effectively screen and treat substance use in elderly prostate cancer patients, policies for enhancing utilization of substance use treatment by elderly cancer patients are needed. INTRODUCTION AND OBJECTIVES: Accurate estimates of baseline life expectancy are required to better inform prostate cancer treatment decisions and avoid over-and under-treatment. The Veterans Health Administration (VHA) cares for patients with prostate cancer with a higher burden of comorbidity than seen in the community. It can be challenging to select appropriate management for patients with increasing comorbidity burden without relevant survival data. Although many models exist to predict life expectancy in men with prostate cancer, few are specific to the VHA population or easily implemented in the clinic setting.
METHODS: Using the national VHA electronic health records, we identified all patients 18 years or older diagnosed with prostate cancer between 2000 and 2013. Patient demographics, comorbidities, and tumor staging information were abstracted. Overall survival information was calculated using the VA National Death Index with follow-up through 2015. We stratified patients by treatment type, number of comorbidities and D'Amico Risk Classification. We plotted visual estimates of overall survival using Kaplan-Meier methods and represented 10-year life expectancy cut-offs in table and heat map formats.
RESULTS: We identified 181,009 total patients, of whom 126,461 had complete oncologic data. The majority of patients were 60-74 years of age with a median of one comorbidity, and 38% were diagnosed with low risk prostate cancer. Kaplan-Meier analysis illustrated the negative impact of increasing comorbidities and cancer risk on survival, summarized further in table format.
CONCLUSIONS: Life expectancy estimates are essential to providing high-quality patient-centered prostate cancer care. We have developed an accessible tool to enhance medical decision-making for VHA patients with prostate cancer that can be easily adopted into routine clinical use. 
